COVID - 19COVID-SMELLNCT07190911
Efficacy of Olfactive Training on Loss of Smell and Taste Caused by SARS CoV2 COVID-19 (Covid-Smell)
A study testing Olfactory rehabilitation consists of smelling a series of spices every day for 2 months in people with COVID - 19, run by Centre Hospitalier Universitaire de la Guadeloupe at 1 site in Guadeloupe.
Trial summary
The purpose of this study is to evaluate efficiency of two months of olfactive training on olfactory and taste loss secondary to covid-19. We will compare 2 groups : olfactive training group versus no olfactive training group. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID - 19
- What is being tested?
- Olfactory rehabilitation consists of smelling a series of spices every day for 2 months
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteGuadeloupe
- Study dates
- 18 Nov 2020to 9 Mar 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- SARS-CoV-2 infection suspect or confirmed
- supported by CHU Guadeloupe
- with brutal olfactory or taste loss
- affiliated or beneficiary of a social security scheme
- informed consent signed
Who cannot join
- recent rhinosinusitis, less than 6 months
- lingual pathology
- communication disorder
- Patients subject to a justice safeguard
- Allergy to several spices that are part of the rehabilitation set
- Pregnant or breastfeeding women
- Absence of signed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy of Olfactive Training on Loss of Smell and Taste Caused by SARS CoV2 (Covid-Smell)
The purpose of this study is to evaluate efficiency of two months of olfactive training on olfactory and taste loss secondary to covid-19. We will compare 2 groups : olfactive training group versus no olfactive training group.
Read the detailed description
The purpose of this study is to evaluate efficiency of two months of olfactive training on olfactory and taste loss secondary to covid-19. We will compare 2 groups : olfactive training group versus no olfactive training group.
- Conditions
- COVID - 19
- Being tested
- Olfactory rehabilitation consists of smelling a series of spices every day for 2 months
- Keywords
- Covid-19, olfactory training, olfactory and taste loss
- Medical subject headings
- COVID-19, Anosmia, Ageusia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Olfactory rehabilitation consists of smelling a series of spices every day for 2 monthsOther
Olfactory rehabilitation consists of smelling a series of spices every day for 2 months: vanilla, coffee, dill, thyme, cinnamon, cloves, lavender, coriander, light vinegar, mint, and cumin.
This rehabilitation is based on the protocols proposed by SFORL (French ORL society) and Oleszkiewicz et al.8
Allergies to certain spices will be noted at the start of the study:
- in known allergy: change by another spice which belongs to the same chemical category.
- in case of allergies to several scents: patient is not included in the study.
- in case of allergy appearing during participation: clinical evaluation by ENT, change by another spice which belongs to the same chemical category.
- in case of allergies to several scents occuring during participation: patient is excluded from the study.
| Study group | Role | What they receive |
|---|---|---|
| olfactory training arm | Experimental | with a daily olfactory training during 2 month Receives: Other: Olfactory rehabilitation consists of smelling a series of spices every day for 2 months |
| no olfactory training | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Taste and Smell Survey (TSS).
Patients will have this auto evaluation scale at the inclusion (D0) and 2 month after inclusion (D60).
Measured: Baseline and 2 months
Secondary outcomes (2)
Sniffin' stick test :
The Sniffin' Stick Test assesses the sense of smell by measuring odor detection threshold, discrimination, and identification, and is used for diagnosing and monitoring olfactory disorders.
Measured: 2 month
Olfaction and taste evolution evaluated with a daily visual scale
Visual analogue scale from 0 to 10 to assess dysosmia and dysgeusia, with 0 indicating normal function and 10 indicating complete deficit.
Measured: Every day from inclusion to 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2025
- Study start18 Nov 2020
- Primary completion9 Mar 2022
- Study completion9 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID - 19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- To prove this efficiency, a parallel prospective comparative study appear to be one of the best the way.
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Suzy Duflo, MD PhD, Principal investigator, CHU de la Guadeloupe
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07190911
- Sponsor's protocol ID
- PAP_RI2_2020/17
- Other IDs
- 2020-A02606-33
- Acronym
- COVID-SMELL
- Status last verified
- Sep 2025
- First submitted
- 22 Sep 2025
- Last updated
- 2 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Olfactive Training on Loss of Smell and Taste Caused by SARS CoV2 (Covid-Smell)
- ClinicalTrials.gov ID
- NCT07190911
- Acronym / sponsor ID
- COVID-SMELL / PAP_RI2_2020/17
- Conditions
- COVID - 19
- Keywords
- Covid-19, olfactory training, olfactory and taste loss
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de la GuadeloupeUniversity, hospital or other
- Study start
- 18 Nov 2020 (actual)
- Primary completion
- 9 Mar 2022 (actual)
- Study completion
- 9 Mar 2022 (actual)
- First posted
- 24 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate efficiency of two months of olfactive training on olfactory and taste loss secondary to covid-19. We will compare 2 groups : olfactive training group versus no olfactive training group.
Detailed description
The purpose of this study is to evaluate efficiency of two months of olfactive training on olfactory and taste loss secondary to covid-19. We will compare 2 groups : olfactive training group versus no olfactive training group.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (care provider)
- Number of arms
- 2
- Model description
- To prove this efficiency, a parallel prospective comparative study appear to be one of the best the way.
| Arm | Type | Receives |
|---|---|---|
| olfactory training arm | Experimental | Other: Olfactory rehabilitation consists of smelling a series of spices every day for 2 monthswith a daily olfactory training during 2 month |
| no olfactory training | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- SARS-CoV-2 infection suspect or confirmed
- supported by CHU Guadeloupe
- with brutal olfactory or taste loss
- affiliated or beneficiary of a social security scheme
- informed consent signed
Key exclusion criteria (7 listed)
- recent rhinosinusitis, less than 6 months
- lingual pathology
- communication disorder
- Patients subject to a justice safeguard
- Allergy to several spices that are part of the rehabilitation set
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Olfactory rehabilitation consists of smelling a series of spices every day for 2 monthsOlfactory rehabilitation consists of smelling a series of spices every day for 2 months: vanilla, coffee, dill, thyme, cinnamon, cloves, lavender, coriander, light vinegar, mint, and cumin. This rehabilitation is based on the protocols proposed by SFORL (French ORL society) and Oleszkiewicz et al.8 Allergies to certain spices will be noted at the start of the study: * in known allergy: change by another spice which belongs to the same chemical category. * in case of allergies to several scents: patient is not included in the study. * in case of allergy appearing during participation: clinical evaluation by ENT, change by another spice which belongs to the same chemical category. * in case of allergies to several scents occuring during participation: patient is excluded from the study. | Other | olfactory training arm |
Primary outcome
Taste and Smell Survey (TSS).
Time frame: Baseline and 2 months
Patients will have this auto evaluation scale at the inclusion (D0) and 2 month after inclusion (D60).
2 secondary outcomes
Sniffin' stick test :
Time frame: 2 month
Olfaction and taste evolution evaluated with a daily visual scale
Time frame: Every day from inclusion to 2 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2025.
- Medical thesis of Ms. Nordera, entitled "Study on the Effectiveness of Olfactory Rehabilitation for Dysosmia and Dysgeusia Following SARS-CoV-2 InfectionLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for COVID - 19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Suzy Duflo, MD PhD principal investigator
CHU de la Guadeloupe
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Olfactory rehabilitation consists of smelling a series of spices every day for 2 months in people with COVID - 19, run by Centre Hospitalier Universitaire de la Guadeloupe at 1 site in Guadeloupe.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Guadeloupe. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Taste and Smell Survey (TSS). (time frame: Baseline and 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2025.